ArticlePharmaceuticals (Basel, Switzerland)2024
Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094568 (Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Headline: Fracture Risk in Type 2 Diabetes: Systematic Review of Cardiovascular Outcome Trials with Glucagon Like Peptide Receptor Agonists.Current osteoporosis reports · 2025Pooled it
- Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test.Diagnostics (Basel, Switzerland) · 2026Article
- The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism.International journal of molecular sciences · 2026Review
- The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in musculoskeletal disease · 2026Article
- Weight loss induced bone loss: mechanism of action and clinical implications.Bone research · 2025Review
- Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Review
- Recent Updates on Diabetes and Bone.International journal of molecular sciences · 2025Review
- Sarcopenic obesity and weight loss-induced muscle mass loss.Current opinion in clinical nutrition and metabolic care · 2025Review
- Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs.Molecular biology reports · 2025Article
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now.Cells · 2025Review
- Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.